Q-omics provides the consensus-scored TIMM13 profile across patient tissues and cancer cell-line models. TIMM13 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TIMM13 is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, TIMM13 protein abundance shows 35,029 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, BLCA, and GBM as cancer lineages where TIMM13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TIMM13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TIMM13 survival associations across molecular data types. TIMM13 RNA expression shows survival associations in the most cancer types (27), followed by mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TIMM13 RNA expression–survival associations across cancer types. High TIMM13 expression shows unfavorable associations in UVM, ACC, SKCM, UCS, KICH and LIHC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify UVM as the clearest survival context for TIMM13 RNA expression.
This table summarizes TIMM13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 12. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TIMM13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TIMM13 shows higher tumor expression in BLCA, COAD, LIHC, STAD, LUSC and UCEC. The BLCA box plot shows higher TIMM13 RNA expression in tumor versus normal tissue (log2 FC = +1.240, t-test p < 0.001).
This table shows molecular features associated with TIMM13 in patient tissues and cancer cell lines. In patient samples, TIMM13 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TIMM13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
